Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04REV
|
|||
| Former ID |
DIB002546
|
|||
| Drug Name |
CDX-1307
|
|||
| Synonyms |
BHCG-VAC; BetaHCG-VAC; MDX-1307; Dendritic cell targeted hCG-beta vaccine, Medarex; B11-hCG-beta, Medarex; Antigen-presenting cell-targeted vaccine (injectable, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (intradermal, cancer), Celldex Therapeutics; Antigen-presenting cell-targeted vaccine (iv, cancer), Celldex Therapeutics
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Bladder cancer [ICD-11: 2C94; ICD-9: 188] | Phase 2 | [1] | |
| Company |
Medarex Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Choriogonadotropin beta (CG-beta) | Target Info | . | [2] |
| WikiPathways | Peptide hormone biosynthesis | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01094496) A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study). U.S. National Institutes of Health. | |||
| REF 2 | CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer. Expert Rev Vaccines. 2011 Jun;10(6):733-42. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.